List of Excipients in Branded Drug CIPROFLOXACIN AND FLUOCINOLONE ACETONIDE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Xspire Pharma LLC	CIPROFLOXACIN AND FLUOCINOLONE ACETONIDE	ciprofloxacin and fluocinolone acetonide	42195-128	GLYCERIN	2030-03-24
Xspire Pharma LLC	CIPROFLOXACIN AND FLUOCINOLONE ACETONIDE	ciprofloxacin and fluocinolone acetonide	42195-128	POLYSORBATE 80	2030-03-24
Xspire Pharma LLC	CIPROFLOXACIN AND FLUOCINOLONE ACETONIDE	ciprofloxacin and fluocinolone acetonide	42195-128	POVIDONE K90	2030-03-24

Ciprofloxacin and Fluocinolone Acetonide: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: September 25, 2026

Ciprofloxacin and fluocinolone acetonide otic products combine an antibacterial fluoroquinolone with a corticosteroid for acute otitis media in pediatric patients with tympanostomy tubes. The reference product, Otovel, is a preservative-free, single-dose otic solution containing ciprofloxacin hydrochloride equivalent to 0.3% ciprofloxacin and fluocinolone acetonide 0.025%.[1]

The strongest commercial opportunities are in generic or authorized-generic development, preservative-free pediatric otic delivery, unit-dose packaging, manufacturing-cost reduction, and differentiated formulations that improve residence time without increasing local irritation. The excipient platform is relatively simple, which reduces formulation complexity but limits opportunities to create broad composition-of-matter protection.

What is ciprofloxacin and fluocinolone acetonide otic solution?

Ciprofloxacin and fluocinolone acetonide otic solution is a topical antibacterial and corticosteroid combination. Otovel is indicated for acute otitis media in pediatric patients aged six months and older with tympanostomy tubes.[1]

Attribute	Reference product
Brand	Otovel
Active ingredients	Ciprofloxacin hydrochloride and fluocinolone acetonide
Strength	0.3% ciprofloxacin and 0.025% fluocinolone acetonide
Dosage form	Otic solution
Administration	0.25 mL per affected ear twice daily for seven days
Patient population	Pediatric patients aged six months and older
Primary indication	Acute otitis media with tympanostomy tubes
Packaging	Single-dose vials
Regulatory application	NDA 209673
FDA approval	September 15, 2016
Preservative status	Preservative-free

The product is administered through a tympanostomy tube, allowing the formulation to reach the middle ear. That route creates tighter constraints on excipient selection than many external-ear products. Formulators must control irritation, microbial quality, pH, osmolality, viscosity, extractables, and compatibility with ear tubes.

What excipients are used in Otovel?

The labeled inactive ingredients are glycerin, povidone, polysorbate 80, and water for injection.[1]

Excipient	Likely formulation function	Commercial relevance
Glycerin	Tonicity adjustment, solvent, humectant	Supports comfort and physical stability
Povidone	Solubilizer, viscosity modifier, wetting aid	Can improve drug uniformity and reduce precipitation
Polysorbate 80	Surfactant and wetting agent	Supports fluocinolone acetonide dispersion or solubilization
Water for injection	Aqueous vehicle	Supports sterile manufacture and microbiological control

The active ingredients have different physicochemical profiles. Ciprofloxacin hydrochloride is comparatively water-compatible, while fluocinolone acetonide is a low-dose corticosteroid with limited aqueous solubility. The formulation therefore must maintain ciprofloxacin availability while keeping the corticosteroid uniformly distributed or solubilized at a very low concentration.

The reference excipient system is commercially attractive because it avoids a complex lipid vehicle, alcohol-heavy solvent system, or multidose preservative strategy. The tradeoff is limited room for substitution without changing critical quality attributes.

How should an excipient strategy be designed for this drug combination?

The principal excipient strategy should preserve four attributes: corticosteroid uniformity, ciprofloxacin chemical stability, low pediatric irritation, and sterile single-dose delivery.

Solubility and drug distribution

Fluocinolone acetonide is the primary formulation challenge. A developer can evaluate:

• Povidone grade and molecular weight.
• Polysorbate 80 concentration.
• Alternative nonionic surfactants.
• Cyclodextrin systems.
• Polyethylene glycol or propylene glycol cosolvents.
• Hydroxypropyl cellulose or low-level polymeric viscosity modifiers.
• Micellar or nanosized delivery systems.

The preferred approach is a low-excipient system that achieves content uniformity without increasing ear discomfort. Cyclodextrins may improve corticosteroid solubility, but they also add regulatory and manufacturing complexity. Cosolvents can increase solubilization but may create tolerability problems in the middle ear.

pH control

Ciprofloxacin stability and solubility are pH-dependent. A formulation must also avoid an acidic or alkaline environment that could increase local irritation. The target pH should be established through stability and tolerability studies rather than copied from the reference product.

Buffer selection is a potential differentiation area. Acetate, citrate, phosphate, and low-capacity buffer systems could produce different stability, osmolality, and tissue-tolerability profiles. A low-buffer-capacity formulation may reduce the risk of persistent pH disturbance after administration.

Viscosity and middle-ear residence time

The reference product is a solution designed for dropwise administration. A moderate increase in viscosity could improve retention at the tympanostomy tube and reduce drainage. Candidate polymers include povidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and carbomers.

The opportunity is commercially relevant but technically constrained. Excessive viscosity can:

• Impede delivery through narrow tympanostomy tubes.
• Increase dosing variability.
• Complicate vial filling.
• Reduce patient acceptance.
• Create residual material in the ear canal.
• Affect the in vitro release or distribution profile.

A modest viscosity increase is more defensible than a gel-forming system unless clinical data establish a meaningful benefit.

Tonicity and local tolerability

Glycerin provides a straightforward route to osmolality adjustment. Developers should optimize osmolality rather than simply match the reference formulation. Hyperosmolar products may cause stinging, while markedly hypotonic products may create tolerability and stability concerns.

A pediatric otic product should be assessed for:

• Immediate pain or burning.
• Ear-canal irritation.
• Middle-ear tissue response.
• Compatibility with tympanostomy tube materials.
• Effects after repeated dosing.
• Potential impact on hearing-related behavior in young children.

Preservative-free design

Preservative-free packaging is strategically important. The product is used in children and reaches the middle ear through a tube. A multidose preserved format could lower packaging cost but would introduce preservative-tolerability and microbiological risks.

Unit-dose packaging also reduces the need for antimicrobial preservatives and limits cross-contamination. The main disadvantages are higher packaging cost, more material consumption, and greater fill-finish complexity.

What formulations are protected by the ciprofloxacin-fluocinolone patent estate?

The relevant protection is expected to center on the combination, concentration range, otic use, formulation composition, and manufacturing or packaging features rather than on the individual active ingredients.

Ciprofloxacin and fluocinolone acetonide are both established compounds with no meaningful new-molecule exclusivity remaining. Commercial protection therefore depends on:

1. Combination-product patents.
2. Formulation patents.
3. Method-of-use claims.
4. Manufacturing and sterile-fill processes.
5. Packaging or unit-dose delivery claims.
6. Regulatory exclusivity associated with the approved product.

The FDA Orange Book is the controlling public source for listed patents and expiration data for NDA 209673.[2] A current freedom-to-operate analysis must review the live Orange Book entries, patent-family continuations, terminal disclaimers, pediatric extensions, and any litigation settlements. A formulation developer should not assume that a change in excipient concentration avoids infringement. Claims may cover ranges, functional limitations, or use of the combination in tympanostomy-tube patients.

How strong is the patent estate?

The estate is likely stronger against a direct copy than against a materially differentiated formulation. A generic developer using the same active ingredients, strengths, route, indication, and comparable excipient architecture faces greater risk than a company developing a modified-release, higher-viscosity, or alternative-container product.

Patent strength depends on claim scope and validity, not the number of listed patents. The principal technical vulnerability of the estate is that many excipient choices are conventional. A patent claim requiring a specific concentration window, stability profile, particle-size distribution, or manufacturing condition may be more defensible than a broad claim to an aqueous combination of the two actives.

When did Otovel lose regulatory exclusivity?

Otovel received FDA approval in 2016. The product's standard new-drug exclusivity period was distinct from patent protection and did not itself create long-term market exclusivity. For a non-new-molecular-entity product, the relevant FDA exclusivity framework generally centers on three-year exclusivity for a new clinical investigation essential to approval.[3]

The commercial entry date depends on the interaction of:

• FDA regulatory exclusivity.
• Orange Book patent expiration.
• Paragraph IV litigation.
• Any 30-month stay.
• ANDA approval timing.
• Settlement terms.
• Pediatric or other statutory extensions.

FDA exclusivity should therefore be treated as an early post-approval barrier, while patent expiration and litigation determine the longer commercial runway.

What is the Orange Book status of ciprofloxacin and fluocinolone acetonide?

The Orange Book lists approved drug products and patent information submitted by NDA holders.[2] For Otovel, the relevant review should cover:

Review item	Business implication
Listed patents	Defines potential ANDA certification obligations
Expiration dates	Establishes the nominal patent barrier
Pediatric extensions	May move the effective expiry date
Patent-use codes	Determines whether a proposed label can carve out a patented use
Delisted or expired patents	Can materially change generic entry risk
NDA holder changes	May affect litigation and licensing strategy

Patent status must be checked against the current Orange Book and the underlying USPTO records. A listed patent's nominal expiration date does not by itself establish freedom to launch because terminal disclaimers, patent-family claims, regulatory stays, and litigation settlements can alter the practical launch date.

Which companies are challenging the product?

Publicly available FDA and court records should be reviewed for ANDA applicants, Paragraph IV notices, and litigation involving Otovel. The commercial market does not require a large number of challengers for price erosion. One approved generic with adequate supply can materially reduce the branded product's volume and net price.

The most likely challenger profiles are:

• Established ophthalmic and otic generic manufacturers.
• Companies with sterile liquid fill-finish capacity.
• Contract development and manufacturing organizations with preservative-free unit-dose capability.
• Specialty generic companies focused on pediatric or local-delivery products.
• International manufacturers entering through U.S. ANDA partnerships.

A direct ANDA challenge is more probable than a biosimilar pathway because the product is a small-molecule combination, not a biologic.

What generic entry risks exist?

A direct generic would likely compete on price while matching the reference product's strength, route, indication, and dosing schedule. The key technical risks include:

• Demonstrating chemical and physical equivalence.
• Establishing uniform distribution of fluocinolone acetonide.
• Matching preservative-free microbiological quality.
• Showing appropriate in vitro performance.
• Qualifying single-dose vial components.
• Controlling silicone oil, particulates, and extractables.
• Demonstrating container-closure integrity.
• Supporting pediatric otic safety.

For a topical otic product, regulatory approval may require more than a simple oral-style bioequivalence approach. FDA product-specific guidance, if applicable, controls the evidence package and can require comparative physicochemical, microbiological, pharmacokinetic, pharmacodynamic, or clinical testing.[4]

The most credible generic launch scenario is a substantially similar preservative-free solution in the same single-dose format. A visibly different formulation may avoid some patent claims but increase regulatory development cost.

What commercial opportunities exist in excipient innovation?

Lower-cost preservative-free unit doses

The clearest near-term opportunity is cost reduction without changing the clinical use profile. Improvements may involve:

• Lower-cost vial resin.
• Smaller fill volume.
• Simplified secondary packaging.
• Automated vial loading.
• Reduced overfill.
• Improved sterile-fill yield.
• Alternative blister or strip packaging.

Packaging economics matter because the active ingredients are inexpensive relative to sterile manufacturing and distribution.

Differentiated viscous solutions

A moderately viscous formulation could improve retention and reduce post-dose leakage. The product would need to remain compatible with the tympanostomy tube and support accurate dosing.

Extended-residence formulations

Thermosensitive gels, mucoadhesive systems, and in situ gelling vehicles could reduce dosing frequency. Their development risk is higher because the product must avoid tube obstruction, excessive middle-ear residence, and unpredictable drug release.

Device-led differentiation

A metered-dose applicator or prefilled delivery device could improve dose consistency. Device protection may be available through patents covering the applicator, dose chamber, or combination of the device with the formulation.

Pediatric adherence products

A product with reduced leakage, less stinging, or easier administration could support premium pricing even without a new active ingredient. The commercial value would be greatest if the formulation reduced administration burden for caregivers.

How does this product compare with competing otic therapies?

Product category	Typical commercial position	Excipient opportunity
Ciprofloxacin-only otic products	Lower-cost antibacterial therapy	Price competition and preservative-free delivery
Ciprofloxacin plus dexamethasone	Established antibiotic-steroid competitor	Different corticosteroid profile and patent estate
Ciprofloxacin plus fluocinolone acetonide	Combination product for tympanostomy-tube patients	Pediatric tolerability, unit-dose packaging, retention
Aminoglycoside-steroid products	Older competitive class	Greater focus on safety and hearing-related concerns
Ofloxacin products	Broad generic availability	Primarily price and supply competition

The closest commercial comparison is ciprofloxacin/dexamethasone otic therapy. A fluocinolone acetonide product may differentiate through steroid selection, formulation profile, packaging, or label-specific positioning rather than through antibacterial activity alone.

What licensing deals could create value?

Potential licensing structures include:

• Regional rights for a generic or branded-generic version.
• Formulation licensing for an improved-residence vehicle.
• Supply agreements for sterile unit-dose filling.
• Device partnerships for metered otic administration.
• Authorized-generic arrangements with the NDA holder.
• Co-development agreements for pediatric otic products.

The strongest licensing asset is a formulation that combines regulatory similarity with a clinically measurable benefit. A novel excipient alone is unlikely to command premium economics unless it improves stability, dosing frequency, tolerability, or manufacturing yield.

What manufacturing and IP barriers matter most?

The principal manufacturing barriers are sterile processing, low-dose corticosteroid uniformity, surfactant control, vial compatibility, and container-closure integrity. The principal IP barriers are combination-product claims, formulation ranges, method-of-use claims, and device claims.

A successful developer should prioritize:

1. Early excipient compatibility screening.
2. Robust content-uniformity methods for fluocinolone acetonide.
3. Container-closure and extractables testing.
4. Tube-delivery compatibility.
5. Stability under shipping conditions.
6. Patent-family and Orange Book review before formulation lock.
7. Commercial-scale sterile-fill qualification.

What is the revenue exposure for the branded product?

Otovel-specific revenue is not separately disclosed in the public filings of its commercial owners. Market exposure is therefore best assessed through prescription volume, payer coverage, wholesale acquisition cost, and the number of approved or pending competitors.

Revenue risk would be high after generic entry because the product contains inexpensive, established active ingredients and uses a conventional aqueous vehicle. Brand defense depends on formulation differentiation, supply reliability, payer contracting, clinical positioning, and any enforceable patent or settlement protection.

Key Takeaways

• Otovel is a preservative-free, single-dose otic solution containing ciprofloxacin 0.3% and fluocinolone acetonide 0.025%.
• Glycerin, povidone, polysorbate 80, and water for injection form the core excipient platform.
• The main technical challenge is maintaining uniformity and stability of the low-dose corticosteroid in an aqueous system.
• The most practical commercial opportunities are generic entry, lower-cost unit-dose packaging, moderate-viscosity formulations, and device-led differentiation.
• Patent protection is likely concentrated in combination, formulation, use, manufacturing, and delivery claims rather than in the active ingredients.
• Direct generic competition presents greater risk than biosimilar competition because this is a small-molecule combination product.
• The most valuable formulation innovation would reduce dosing burden, improve retention, reduce irritation, or lower sterile manufacturing cost.

FAQs

Is ciprofloxacin and fluocinolone acetonide a biologic?

No. It is a small-molecule combination product. Generic applicants would generally use the ANDA pathway rather than the biosimilar pathway.

Is Otovel preservative-free?

Yes. The labeled product is supplied as a preservative-free, single-dose otic solution.[1]

Can polysorbate 80 be replaced in a generic formulation?

Potentially, but substitution may affect solubility, particle formation, stability, irritation, and regulatory comparability. The replacement would require formulation and product-performance support.

What is the main patent risk for a ciprofloxacin-fluocinolone generic?

The principal risk is infringement of listed formulation, combination-use, or delivery claims, particularly when the proposed product closely copies the reference formulation and label.

Is an extended-release formulation commercially attractive?

Yes, if it reduces administration frequency without obstructing tympanostomy tubes or increasing middle-ear irritation. The regulatory, clinical, and manufacturing burden would be materially higher than for a direct generic solution.

References

1. U.S. Food and Drug Administration. (2022). Otovel (ciprofloxacin hydrochloride and fluocinolone acetonide) otic solution prescribing information. FDA.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Frequently asked questions on patents and exclusivity. FDA.

4. U.S. Food and Drug Administration. (2024). Product-specific guidances for generic drug development. FDA.